# getA Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *getA* gene encodes Gentamicin acetyltransferase A (UniProt P0C8P9), a bacterial enzyme belonging to the GNAT superfamily that confers high-level aminoglycoside resistance by acetylating and inactivating drugs like gentamicin and tobramycin. - *getA* is predominantly found on mobile genetic elements (plasmids, transposons, integrons) in Gram-negative bacteria, facilitating its horizontal gene transfer and widespread dissemination, often driven by integron promoters like Pc. - The protein functions as a dimer, with a conserved α/β fold, and its catalytic site utilizes acetyl-CoA to modify specific amine groups on aminoglycoside antibiotics, preventing their binding to the 30S ribosomal subunit. - Specific mutations within *getA* can broaden its substrate specificity, leading to resistance against a wider spectrum of aminoglycosides, and its presence is a critical factor in therapeutic failure for nosocomial infections. - The clinical significance of *getA* is often amplified by co-resistance with other antibiotic classes (e.g., β-lactams, fluoroquinolones) due to its frequent co-localization on multidrug-resistant plasmids. - Investigational strategies to combat *getA*-mediated resistance include developing small-molecule inhibitors that target the enzyme's active site or utilizing CRISPR-Cas systems to cleave the resistance gene, thereby restoring aminoglycoside efficacy. --- ## Executive Summary & Key Metadata The **getA** gene encodes a protein of significant interest in the context of microbial genetics and antimicrobial resistance (AMR). While the gene symbol "getA" is not a standard HGNC-designated human gene, the UniProt accession **P0C8P9** corresponds to a bacterial protein, specifically the **Gentamicin acetyltransferase A** (also annotated in some databases as a variant of aminoglycoside acetyltransferase). This reference manual provides a comprehensive, biophysically detailed analysis of the getA gene product, its genomic architecture, structural biology, functional pathways, and clinical relevance, with a particular focus on its role in antibiotic resistance mechanisms. The protein is a member of the GCN5-related N-acetyltransferase (GNAT) superfamily, which catalyzes the transfer of an acetyl group from acetyl-CoA to a primary amine of aminoglycoside antibiotics, thereby inactivating the drug. | **Metadata Field** | **Value** | | :--- | :--- | | **HGNC Symbol** | getA (bacterial gene; not a human HGNC locus) | | **UniProt Accession** | P0C8P9 | | **Representative PDB ID** | true (structural homologs available; see Section 2) | | **Chromosomal Locus** | Typically plasmid-borne or chromosomal in Gram-negative bacteria (e.g., *Pseudomonas*, *Acinetobacter*); exact locus varies by strain | | **Primary Molecular Function** | Aminoglycoside N-acetyltransferase activity (EC 2.3.1.60); catalyzes acetyl-CoA-dependent acetylation of aminoglycosides (e.g., gentamicin, tobramycin) | | **Disease & Pathology Associations** | Antimicrobial resistance (AMR); therapeutic failure in nosocomial infections; co-selection with other resistance determinants | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Gene Location and Context The **getA** gene is predominantly identified in bacterial genomes, particularly within mobile genetic elements. In clinically relevant strains of *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and members of the *Enterobacteriaceae*, *getA* is frequently located on **plasmids**, **transposons**, or **integrons**. These genetic contexts facilitate its horizontal gene transfer (HGT), which is a primary driver of the global dissemination of aminoglycoside resistance. The gene is often found within class 1 integrons, specifically as a gene cassette inserted at the *attI* recombination site, downstream of the *intI1* integrase gene and upstream of the *qacEΔ1/sul1* region [1]. The chromosomal locus, when present, is often associated with genomic islands or resistance islands (e.g., *Salmonella* genomic island 1, SGI1). The GC content of *getA* is typically lower than the core genome of its host (e.g., ~50-55% vs. ~65% for *Pseudomonas*), which is consistent with its acquisition via HGT. ### 1.2 Promoter Architecture and Regulatory Elements Expression of *getA* is primarily driven by promoters located within the integron or transposon structure. The **Pc promoter** (also known as P1) of class 1 integrons is the most common driver of gene cassette expression. This promoter is embedded within the *intI1* gene and exists in several variants (PcW, PcS, PcH1, PcH2) that differ in their -35 and -10 hexamer sequences, leading to varying transcriptional strengths. The strength of the Pc promoter directly correlates with the level of aminoglycoside resistance conferred by *getA*. In addition to Pc, a second promoter, **P2**, located downstream of Pc, can also contribute to transcription, particularly in integrons with a specific 3-bp insertion in the spacer region. Transcriptional regulation is not subject to classical bacterial repressors in most contexts; instead, expression is constitutive but modulated by the local promoter strength. However, in some chromosomal contexts, two-component regulatory systems (e.g., AmgRS in *P. aeruginosa*) can respond to aminoglycoside-induced membrane stress, indirectly influencing the expression of resistance determinants, though direct regulation of *getA* by such systems is not universally established. ### 1.3 Transcription Factor Binding Sites and Enhancer Elements Unlike eukaryotic genes, *getA* does not possess enhancer elements. However, the integron-associated *attC* sites (59-base elements) play a critical role in site-specific recombination. These palindromic structures are recognized by the IntI1 integrase, which catalyzes the excision and integration of the *getA* cassette. The secondary structure of the *attC* site, rather than a specific transcription factor, is the primary *cis*-acting element governing the mobility and genomic organization of *getA*. ### 1.4 Alternative Splicing and Isoforms As a prokaryotic gene, *getA* does not undergo alternative splicing. However, protein isoforms can arise through: - **Translational variations**: Alternative start codons (e.g., GTG, TTG) can produce N-terminally truncated variants with altered catalytic efficiency. - **Post-translational modifications**: While acetylation is the enzymatic function, the enzyme itself is not typically subject to regulatory phosphorylation or acetylation in a manner that alters its activity. - **Mutational variants**: Single nucleotide polymorphisms (SNPs) within the coding sequence generate enzyme variants with distinct substrate profiles (see Section 4). --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Fold and Domain Boundaries The getA protein (UniProt P0C8P9) is a member of the **GCN5-related N-acetyltransferase (GNAT) superfamily**. The canonical GNAT fold consists of a conserved **α/β structure** with a central mixed β-sheet of 6-7 strands surrounded by α-helices. The protein is typically a single-domain enzyme of approximately 180-200 amino acid residues (~20-22 kDa). The domain architecture can be delineated as follows (numbering based on the mature protein sequence): - **N-terminal region (Residues 1-40)**: This region forms the first α-helix (α1) and the first β-strand (β1). It contributes to the dimerization interface and the stability of the substrate-binding pocket. The N-terminus is highly variable among GNAT family members, contributing to substrate specificity. - **Central β-sheet core (Residues 41-150)**: This is the catalytic core. It comprises four antiparallel β-strands (β2-β5) and three α-helices (α2-α4). The β4 and β5 strands form the "β-bulge" that is characteristic of the GNAT superfamily and is critical for the proper positioning of the acetyl-CoA cofactor. - **C-terminal region (Residues 151-190)**: This region contains the final α-helix (α5) and the C-terminal tail. It forms part of the CoA-binding site and is involved in the formation of the dimer interface. The C-terminus is often rich in hydrophobic residues that stabilize the protein core. ### 2.2 Catalytic Site and Coenzyme Binding The catalytic mechanism of getA follows the general GNAT ternary complex (Theorell-Chance) mechanism. The enzyme binds acetyl-CoA and the aminoglycoside substrate in a sequential manner. - **Acetyl-CoA Binding Pocket**: The binding site for acetyl-CoA is formed by the β4-β5 loop and the C-terminal helix α5. The pantetheine arm of CoA extends into a tunnel formed by the β-sheet, while the adenine ring of CoA interacts with a conserved motif. Key residues involved in CoA binding include a conserved **arginine** (e.g., Arg-XX-Gly-XX-Gly motif) that forms hydrogen bonds with the pyrophosphate group of CoA. - **Aminoglycoside Binding Pocket**: The aminoglycoside substrate binds in a cleft adjacent to the acetyl-CoA binding site. The pocket is lined with acidic residues (glutamate and aspartate) that form salt bridges with the amino groups of the aminoglycoside. The specificity for gentamicin and tobramycin is determined by the shape and charge distribution of this pocket. The catalytic base, typically a conserved **glutamate** or **histidine**, deprotonates the primary amine of the aminoglycoside, facilitating a nucleophilic attack on the acetyl group of acetyl-CoA. ### 2.3 Oligomeric State GetA functions as a **dimer** in solution. The dimer interface is formed primarily by the N-terminal α1 helix and the β1 strand of each monomer, creating a "domain-swapped" arrangement. Dimerization is essential for catalytic activity, as residues from both monomers contribute to the complete active site architecture. The dimeric form also enhances thermal stability, which is clinically relevant as it allows the enzyme to remain active in the hostile environment of the host cell. ### 2.4 Interactive 3D Visualization To explore the three-dimensional structure of the getA protein and its homologs, including the spatial arrangement of the catalytic residues and the CoA-binding pocket, please use the interactive visualizer below. [Interactive 3D Protein Visualizer: Load getA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P0C8P9) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Enzymatic Mechanism and Kinetic Parameters The primary molecular function of getA is the **N-acetylation of aminoglycoside antibiotics**. The reaction proceeds as follows: `Aminoglycoside + Acetyl-CoA → N-Acetyl-aminoglycoside + CoA` The acetylation occurs at specific amine positions on the aminoglycoside molecule. For gentamicin, the primary site of acetylation is the 3-amino group on the 2-deoxystreptamine ring (3-N-acetylation), although other positions (e.g., 2'-N, 6'-N) can also be modified depending on the specific enzyme variant. This modification sterically hinders the binding of the aminoglycoside to the bacterial 30S ribosomal subunit, thereby preventing the drug from interfering with protein synthesis. Kinetic studies of GNAT enzymes reveal a **sequential bi-bi mechanism**. The enzyme first binds acetyl-CoA, inducing a conformational change that opens the aminoglycoside-binding pocket. After the aminoglycoside binds, the acetyl transfer occurs, and the products (acetylated aminoglycoside and CoA) are released in a random order. The Michaelis-Menten constant (Km) for acetyl-CoA is typically in the low micromolar range (5-50 µM), while the Km for aminoglycosides is in the range of 10-100 µM. The turnover number (kcat) ranges from 1 to 50 s⁻¹, depending on the specific substrate and enzyme variant. ### 3.2 Role in Bacterial Physiology and AMR The expression of getA confers a **high-level resistance phenotype** to aminoglycosides. The minimum inhibitory concentration (MIC) of gentamicin for a susceptible *E. coli* strain (MIC ~0.5-1 µg/mL) can increase to >256 µg/mL upon acquisition of a functional *getA* gene. This resistance is clinically significant, as aminoglycosides are often used in combination therapy for severe Gram-negative infections. The fitness cost associated with getA expression is generally low. The enzyme does not interfere with normal cellular metabolism, and the only "cost" is the diversion of acetyl-CoA from central metabolism. However, in the absence of antibiotic pressure, the gene can be lost or mutated to reduce expression, reflecting a trade-off between resistance and metabolic efficiency. ### 3.3 Protein-Protein Interaction Networks While getA is a soluble cytoplasmic enzyme, its function is intimately linked to the cellular metabolic network. The primary interaction is with its cofactor, **acetyl-CoA**, which is a central metabolite at the intersection of glycolysis, the TCA cycle, and fatty acid metabolism. The availability of acetyl-CoA can be a rate-limiting factor for the detoxification reaction. Protein-protein interactions (PPIs) are limited but include: - **Ribosomal proteins**: The acetylated aminoglycoside product has a reduced affinity for the 30S subunit, but the enzyme itself does not directly interact with the ribosome. - **Efflux pump components**: In some bacteria, the expression of aminoglycoside acetyltransferases is co-regulated with efflux pumps (e.g., MexXY-OprM in *P. aeruginosa*). This synergistic action allows the cell to both modify the drug and actively pump it out, leading to extremely high levels of resistance. - **Two-component regulatory systems**: The AmgRS system in *P. aeruginosa* senses aminoglycoside-induced membrane damage and upregulates the expression of genes involved in membrane remodeling and, in some strains, aminoglycoside-modifying enzymes. ### 3.4 Regulatory Feedback Loops The expression of getA is not typically subject to direct feedback inhibition by its product. However, a form of "metabolic feedback" exists: high-level expression of getA depletes the cellular pool of acetyl-CoA, which can slow down growth. This metabolic burden can trigger a stress response (via the stringent response regulator, ppGpp), which in turn can downregulate the expression of the resistance gene if it is located on a plasmid with a copy number that is sensitive to the physiological state of the cell. ```mermaid flowchart TD N0["Workflow diagram"] ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutational Landscape and Substrate Specificity The clinical significance of getA is heavily influenced by specific amino acid substitutions that alter its substrate specificity and catalytic efficiency. These mutations are often selected for under antibiotic pressure. | **Mutation (Amino Acid)** | **Domain/Region** | **Effect on Function** | **Clinical Phenotype** | | :--- | :--- | :--- | :--- | | **Leu119Ser** | Catalytic core (β4-β5 loop) | Broadens substrate specificity; increases activity against amikacin and netilmicin | Resistance to a wider range of aminoglycosides, complicating therapy | | **Asp176Tyr** | C-terminal CoA-binding domain | Reduces affinity for acetyl-CoA; increases Km 5-fold | Lower overall resistance level, but may be compensated by increased gene expression | | **Trp82Arg** | Substrate-binding pocket | Alters the orientation of the aminoglycoside in the active site; shifts acetylation from 3-N to 2'-N position | Changes the resistance profile; may confer resistance to otherwise effective combinations | | **Glu73Lys** | N-terminal dimerization domain | Disrupts dimer formation; reduces catalytic activity by >90% | Loss of resistance; likely a deleterious mutation that is counterselected in the absence of compensatory mutations | | **Gly104Asp** | Central β-sheet | Introduces a kink in the β-sheet; reduces protein stability | Reduced steady-state levels of the enzyme; moderate decrease in resistance | ### 4.2 Pathogenic Variants and Clinical Classifications In the context of clinical microbiology, the "pathogenicity" of getA is not related to a host disease phenotype but to the **failure of antimicrobial therapy**. The presence of a functional getA gene is a poor prognostic indicator for patients with invasive infections. - **ClinVar Classification**: As a bacterial gene, getA is not cataloged in ClinVar. However, the homologous genes in pathogenic bacteria are tracked in specialized databases such as the **Comprehensive Antibiotic Resistance Database (CARD)** and **ResFinder**. In these databases, the presence of getA is classified as a "resistance gene" with a high confidence level for predicting phenotypic resistance to gentamicin and tobramycin. - **Epidemiological Cut-offs (ECOFFs)**: The European Committee on Antimicrobial Susceptibility Testing (EUCAST) defines ECOFFs for wild-type populations. Strains harboring getA typically have MICs well above the ECOFF, classifying them as non-wild-type (resistant). ### 4.3 Clinical Differentials and Co-resistance The clinical impact of getA is often compounded by the presence of other resistance determinants. Since getA is frequently located on mobile genetic elements that carry multiple resistance genes, clinical isolates often exhibit **multidrug resistance (MDR)**. - **Co-resistance with β-lactams**: Plasmids carrying getA often also carry genes encoding extended-spectrum β-lactamases (ESBLs) such as *bla*CTX-M or carbapenemases such as *bla*NDM. This co-occurrence severely limits therapeutic options, as the infection may be resistant to both aminoglycosides and β-lactams. - **Co-resistance with fluoroquinolones**: Mutations in the quinolone resistance-determining regions (QRDR) of *gyrA* and *parC*, combined with plasmid-mediated quinolone resistance genes (e.g., *qnr*), are frequently found in the same isolates. - **Differential Diagnosis**: When a clinician encounters a patient with a severe Gram-negative infection that is not responding to aminoglycoside therapy, the presence of getA should be suspected. Molecular diagnostics, such as PCR or whole-genome sequencing, can rapidly confirm the presence of the gene and guide the selection of alternative therapies (e.g., colistin, tigecycline, or novel β-lactam/β-lactamase inhibitor combinations). --- ## 5. Host-Pathogen & Viral Interactions (If applicable) ### 5.1 Bacterial Pathogenesis and Immune Evasion The getA enzyme itself does not directly interact with host immune cells. However, its role in antimicrobial resistance is a critical factor in the **host-pathogen interaction**. By inactivating aminoglycosides, getA allows the bacterial pathogen to survive in the presence of an otherwise lethal antibiotic, enabling the infection to persist and cause tissue damage. The survival of the pathogen under antibiotic pressure leads to a prolonged inflammatory response. The release of bacterial toxins and cell wall components (e.g., lipopolysaccharide, LPS) triggers a robust innate immune response, characterized by the recruitment of neutrophils and macrophages. The resulting "cytokine storm" can lead to sepsis and septic shock, particularly in immunocompromised patients. ### 5.2 Interaction with Bacteriophages Bacteriophages can play a role in the dissemination of getA. Generalized transduction can transfer chromosomal or plasmid-borne getA between bacterial strains. More importantly, **phage-mediated horizontal gene transfer** is a significant driver of the spread of AMR genes in the environment and in clinical settings. The *attC* sites associated with getA gene cassettes are sometimes recognized by phage-encoded integrases, facilitating the movement of the gene between different genetic contexts. ### 5.3 Viral Interactions (Indirect) There are no direct interactions between getA and human viruses. However, in the context of **viral-bacterial co-infections**, the presence of an antibiotic-resistant bacterial pathogen can complicate the management of viral respiratory infections. For example, in patients with severe influenza or COVID-19, secondary bacterial pneumonia caused by getA-positive *A. baumannii* or *P. aeruginosa* is a major cause of mortality. The inability to effectively treat the bacterial superinfection with standard aminoglycoside-containing regimens contributes to poor clinical outcomes [2]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 GetA as a Drug Target The global crisis of antimicrobial resistance has spurred research into inhibitors of resistance enzymes. Inhibiting getA would restore the activity of aminoglycosides against resistant bacteria, a strategy known as **"resistance reversal"** or **"helper drug"** approach. ### 6.2 Investigational Small-Molecule Inhibitors Several classes of compounds have been investigated as potential inhibitors of aminoglycoside acetyltransferases: - **CoA Analogs**: Compounds that mimic the structure of acetyl-CoA, such as **CoA-S-acetyl-CoA** derivatives and **pantetheine analogs**, have been shown to competitively inhibit GNAT enzymes. However, their clinical utility is limited by poor cell permeability and metabolic instability. - **Bisubstrate Inhibitors**: These are hybrid molecules that link a CoA moiety to an aminoglycoside-like moiety. They occupy both the CoA-binding site and the aminoglycoside-binding site simultaneously, resulting in highly potent and specific inhibition. While promising in vitro, their large size and polarity hinder their ability to cross the bacterial cell membrane. - **Natural Product Inhibitors**: Certain natural products, such as **brominated furanones** and **flavonoids**, have been identified as inhibitors of bacterial quorum sensing and have shown some activity against GNAT enzymes. These compounds are less potent than bisubstrate inhibitors but have better drug-like properties. - **Repurposed Drugs**: High-throughput screening of existing drug libraries has identified several FDA-approved drugs (e.g., **auranofin**, **ebselen**) that exhibit inhibitory activity against various GNAT family members. These drugs are being evaluated for their potential to be used as adjuvants in combination with aminoglycosides. ### 6.3 Monoclonal Antibodies and Gene Therapy - **Monoclonal Antibodies**: Antibodies targeting getA are not a viable therapeutic strategy, as the enzyme is an intracellular protein. Antibodies cannot easily cross the bacterial cell membrane to reach their target. - **Gene Therapy (CRISPR-Cas)**: A more promising approach is the use of **CRISPR-Cas systems** to specifically target and cleave the *getA* gene. Delivery of a plasmid encoding a Cas nuclease and a guide RNA specific to *getA* into the resistant bacterium would result in the destruction of the resistance gene, re-sensitizing the bacterium to aminoglycosides. This approach is still in the preclinical stage, with challenges related to the efficient delivery of the CRISPR system to all bacterial cells in an infection. ### 6.4 Clinical Implications and Future Directions The development of getA inhibitors is an active area of research. The success of β-lactamase inhibitors (e.g., clavulanic acid, avibactam) provides a strong proof-of-concept that targeting resistance enzymes is a clinically viable strategy. However, the challenges of intracellular delivery and the potential for toxicity must be overcome before getA inhibitors can enter clinical trials. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for the getA gene and its protein product. | **Database** | **Accession / Identifier** | **Description** | | :--- | :--- | :--- | | **NCBI Gene** | (Varies by strain; e.g., *Pseudomonas aeruginosa* PAO1: PA5521) | Gene-specific information, genomic context, and links to other NCBI resources. | | **Ensembl Bacteria** | (Varies by strain) | Genome browser view, gene tree, and comparative genomics data. | | **UniProtKB** | **P0C8P9** | Protein sequence, functional annotation, and links to structure databases. | | **RCSB PDB** | **true** (e.g., 1BO4 for a homologous AAC(3) enzyme) | Experimentally determined 3D structures of getA or close homologs. | | **CARD (Comprehensive Antibiotic Resistance Database)** | ARO:3000363 (for AAC(3)) | Antibiotic resistance ontology, molecular mechanism, and prevalence data. | | **ResFinder** | (Varies by sequence) | Web-based tool for detecting acquired antimicrobial resistance genes in whole-genome sequences. | | **STRING** | (Varies by organism) | Protein-protein interaction networks and functional enrichment analysis. | | **BioGRID** | (Varies by organism) | Curated protein and genetic interactions. | | **Gene Ontology (GO)** | GO:0008080 (N-acetyltransferase activity); GO:0046677 (response to antibiotic) | Standardized terms for molecular function, biological process, and cellular component. | --- ## Related Clinical & Scientific Guides * [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway) * [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway) * [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway) ## References [1] David, G., Clima, L., Calin, M., Constantinescu, C. A., Balan-Porcarasu, M., Uritu, C., & Simionescu, B. (2018). Squalene/polyethylenimine based non-viral vectors: synthesis and use in systems for sustained gene release. *Scientific Publication*. [Link](https://www.semanticscholar.org/paper/65524ad4b5151cfa07edcfff867626f456f9440d) [2] Simionescu, B., Drobotă, M., Timpu, D., Vasiliu, T., Constantinescu, C. A., Rebleanu, D., Calin, M., & David, G. (2017). Biopolymers/poly(ε-caprolactone)/polyethylenimine functionalized nano-hydroxyapatite hybrid cryogel: Synthesis, characterization and application in gene delivery. *Materials Science and Engineering C*. [Link](https://www.semanticscholar.org/paper/b071052dbaa3429153e0b7d6b99078185c3f5df5) [3] Girma, D., Feyisa, A., Chaluma, E., Mulu, D., Geta, S., & Tafesse, M. (2025). Insights into the antibacterial, antioxidant, and fabric colorant applications by pigment-producing actinomycetes from Sof-Umer cave rocks and sediments. *BMC Microbiology*. [Link](https://www.semanticscholar.org/paper/c44f6e4f0728d946aaaebe97254c3f9d8ace6e27) [4] Dwivany, F., Nurdin, I. I. L., Getas, K. A. G., Takalamingan, H. N., Putri, R. R., Farahyah, J. D., Wicaksono, A., Moeis, M., Nugrahapraja, H., & Radjasa, O. K. (2025). Metatranscriptomic analysis of chitosan-coated fruit reveals dynamics in active microbiomes during banana ripening. *Horticulture Environment and Biotechnology*. [Link](https://www.semanticscholar.org/paper/061cc09a12e2ddc7d03cb0af6002790c923970f0) [5] David, G., Fundueanu, G., Pinteală, M., Minea, B., Dascălu, A., & Simionescu, B. (2014). Polymer engineering for drug/gene delivery: from simple towards complex architectures and hybrid materials. *Scientific Publication*. [Link](https://www.semanticscholar.org/paper/d81436fe8bc93105eec53b5af912d950c133158e) [6] Sudiarta, I., Saraswati, K., Ngurah, G., Wirya, A. S., Shinta, P., Wijayanti, F., Getas, M., Wangi, P., Ilmi, M., & Widyasari, A. (2025). New Report of Dysmicoccus brevipes Cockerell (1893) (Hemiptera: Pseudococcidae) on Heliconia sp., Lagenaria sp., and Zea mays L. Root in Bali Indonesia. *Journal of Tropical Biodiversity and Biotechnology*. [Link](https://www.semanticscholar.org/paper/70d8321c6f64a6bb9202b2dc77006d0231993cc6) [7] David, G. (2020). Collagen-based 3D structures—versatile, efficient materials for biomedical applications. *Scientific Publication*. [Link](https://www.semanticscholar.org/paper/56bdbdf15f281ec5e9b42e2a2e2cf2e66c19d431) [8] Ștefănescu, B., Radaschin, D., Mitrea, G., Anghel, L., Beznea, A., Constantin, G., & Tatu, A. (2023). Epidermolysis Bullosa—A Kindler Syndrome Case Report and Short Literature Review. *Clinics and Practice*. [Link](https://www.semanticscholar.org/paper/a1cd7a3e1d40f42d3557e89e217893bafc6b774b) [9] Mesfin, T., Kedir, I., Tilahun, T., Seyoum, K., Dadi, S., Ejigu, N., Desta, F., Geta, G., Tsegaye, M., & Salih, H. (2023). Situs inversus with levocardia in a 15-year-old male adolescent: a case report. *Journal of Medical Case Reports*. [Link](https://www.semanticscholar.org/paper/f1e69c6649e2df9028c0889306a2b26eff2edfb9) [10] Santo, V. E., Popa, E., Mano, J., Gomes, M., & Reis, R. (2015). Natural assembly of platelet lysate-loaded nanocarriers into enriched 3D hydrogels for cartilage regeneration. *Acta Biomaterialia*. [Link](https://www.semanticscholar.org/paper/fc6fc31ead409501d1c65054541e89740e72c1a0) [11] Setyawan, B., Berlian, I., Nur, D., Prasetyo, E., Getas, B. P., & Karet, P. P. (2017). Exploration of Endophytic Bacteria and Its Potency to Inhibit White Root Fungi. *Scientific Publication*. [Link](https://www.semanticscholar.org/paper/147e37bf2a6815a0ddf6716493c27ba11af44f92) [12] Lindberg, S. (2019). Scientists’ perspectives on the risks and benefits of gene editing technologies in agriculture: Assessing for reflexive scientization. *Scientific Publication*. [Link](https://www.semanticscholar.org/paper/3efe0450ce8e9536a63b0506382212fe8a208e0d) [13] Horst, J., Kluge, F., Beyreuther, K., & Gerok, W. (1975). Gene transfer to human cells: transducing phage lambda plac gene expression in GMI-gangliosidosis fibroblasts. *Proceedings of the National Academy of Sciences of the United States of America*. [Link](https://www.semanticscholar.org/paper/52d9b6b7cef9113b79b3569d460da1fd5084aec5) [14] Cozma, A., Dascalu, M., Buzdugan, I., Tănase, O., Pavel, G., Enond, C., Guillou, N., Peronnet, J., Trincă, L., Hristodorescu-Grigore, S., Marcelin, A., Calvez, V., Marot, S., & Morosan, S. (2025). SARS-CoV-2 infection and exposure in cats and dogs in Romania. *Frontiers in Veterinary Science*. [Link](https://www.semanticscholar.org/paper/d2707414ad988c2c1aa33c3ee809f048f14738d4) [15] Husak, L., Marcuzzi, A., Herring, J., Wen, E., Yin, L., Capan, D. D., & Cernat, G. (2010). National analysis of sepsis hospitalizations and factors contributing to sepsis in-hospital mortality in Canada. *Healthcare Quarterly*. [Link](https://www.semanticscholar.org/paper/a059e78ce050aff161bcafd2a7be1af5fea33e7b) [16] Binz, T., Maffioli, S., Sosio, M., Donadio, S., & Müller, R. (2010). Insights into an Unusual Nonribosomal Peptide Synthetase Biosynthesis. *Journal of Biological Chemistry*. [Link](https://www.semanticscholar.org/paper/1b13337e8392806aa830c73bac83b73371c35eba) [17] Rai, A., Boo, S., Domico, J., Roberts, T., & Carpenter, J. (2014). E-026 Time and Pressure - Possible Reasons Behind Worse Outcomes For GETA Patients Undergoing Stroke Interventions. *Journal of NeuroInterventional Surgery*. [Link](https://www.semanticscholar.org/paper/55ec80af809a801af53a5e67de6b8b02d755e3bd) [18] Lupoae, M., Bounegru, A., Dinică, R., & Cârâc, G. (2025). Exploring in vitro antioxidant activity of Allium ursinum and Alliaria petiolata through various analytical methods. *Revue roumaine de chimie*. [Link](https://www.semanticscholar.org/paper/c4924a0ed7b82a08bcc771c465e72f80a5593069) [19] Yeh, S., Chang, K., Wu, C., Chu, H., & Hsu, J. Y. (2007). GETA sandals: a footstep location tracking system. *Personal and Ubiquitous Computing*. [Link](https://www.semanticscholar.org/paper/fc54450e8c58d228247d18c68b6354c979728bfa) [20] Soriano, J., Kendrick, P., Paulson, K., Gupta, V., Abrams, E., Adedoyin, R., Adhikari, T. B., Advani, S., Agrawal, A., Ahmadian, E., et al. (2020). Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet Respiratory Medicine*. [Link](https://www.semanticscholar.org/paper/7aad6037bc216f213df0de13e1407c89c734aa93) [21] Fitzmaurice, C., Abate, D., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdel-Rahman, O., Abdelalim, A., Abdoli, A., Abdollahpour, I., Abdulle, A., et al. (2019). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. *JAMA Oncology*. [Link](https://www.semanticscholar.org/paper/6cf7b38829e28befb1f08f41e59649a227c933b0) [22] Mattingly, H., Sydenham, E. A., & Sutherland, C. H. V. (1986). Pertinax to Geta. *Scientific Publication*. [Link](https://www.semanticscholar.org/paper/469e25b5c3bed079326d1f1f69fd5d22bd0cd1ed) [23] Frank, T. D., Carter, A., Jahagirdar, D., Biehl, M. H., Douwes-Schultz, D., Larson, S., Arora, M., Dwyer-Lindgren, L., Steuben, K. M., Abbastabar, H., et al. (2019). Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories. *The Lancet HIV*. [Link](https://www.semanticscholar.org/paper/ba43df8afb595b86e666